Clonidine for attention-deficit/hyperactivity disorder

I. Efficacy and tolerability outcomes

Donna R. Palumbo, Floyd R. Sallee, William E. Pelham, Oscar G. Bukstein, W. Burleson Daviss, Michael P. McDermott, Lisa Burrows-MacLean, Peter Como, Martin T. Hoffman, Thomas Lock, Daniel Nelson, Brian McConville, Joanne Janciuras, Stephen A. Bean, Dana Raab, Francis Arnold, Heidi Kipp, Nancy Pearson, Amy Vierhile, Brad Russell & 22 others Katy Tresco, Michael Cannon, Susan Maher, David Marcus, Garrett Riggs, Adelaide Robb, Peter Harris, Irene Richard, Stephen Sulkes, Cox Christopher Cox, Roger Kurlan, Keith Conners, Robert Hunt, Karl Kieburtz, Elisabeth De Blieck, Patricia Lindsay, Larry Preston, Karen Rothenburgh, Elaine Julian-Baros, Connie Orme, Dee Kamp, Lisa Thompson

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

OBJECTIVE: To determine the efficacy and safety of clonidine, used alone or in combination with methylphenidate, in treating attention-deficit/ hyperactivity disorder (ADHD). METHOD: A 16-week, randomized, double-blind, placebo-controlled clinical trial was conducted in 122 children, ages 7 to 12, with any subtype of ADHD, randomly assigned to clonidine, methylphenidate, clonidine in combination with methylphenidate, or placebo according to a 2 × 2 factorial design. In two successive 4-week titration periods, clonidine (or matching placebo) and added methylphenidate (or matching placebo) were adjusted to optimal doses and then continued for 8 weeks. The primary efficacy outcome was changed from baseline to week 16 on the Conners Teachers Abbreviated Symptom Questionnaire. Secondary outcomes included the Conners Abbreviated Symptom Questionnaire for Parents and the Children's Global Assessment Scale. RESULTS: On the Conners Teachers Abbreviated Symptom Questionnaire, clonidine was not found to improve ADHD symptoms, whereas subjects treated with methylphenidate showed significant improvement compared to those not treated with methylphenidate. Subjects treated with clonidine had greater improvements on the Conners Abbreviated Symptom Questionnaire for Parents and Children's Global Assessment Scale, but also a higher rate of sedation compared with subjects not treated with clonidine. CONCLUSIONS: Based on the Conners Teachers Abbreviated Symptom Questionnaire, methylphenidate offers the best combination of efficacy and tolerability for ADHD. Clonidine was well tolerated despite the frequency of sedation and did offer some benefit. Copyright 2008

Original languageEnglish (US)
Pages (from-to)180-188
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume47
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Clonidine
Methylphenidate
Attention Deficit Disorder with Hyperactivity
Placebos
Parents
Controlled Clinical Trials
Surveys and Questionnaires
Safety

Keywords

  • Attentiondeficit/hyperactivity disorder
  • Clinical trials
  • Clonidine
  • Methylphenidate

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Palumbo, D. R., Sallee, F. R., Pelham, W. E., Bukstein, O. G., Daviss, W. B., McDermott, M. P., ... Thompson, L. (2008). Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 47(2), 180-188. https://doi.org/10.1097/chi.0b013e31815d9af7

Clonidine for attention-deficit/hyperactivity disorder : I. Efficacy and tolerability outcomes. / Palumbo, Donna R.; Sallee, Floyd R.; Pelham, William E.; Bukstein, Oscar G.; Daviss, W. Burleson; McDermott, Michael P.; Burrows-MacLean, Lisa; Como, Peter; Hoffman, Martin T.; Lock, Thomas; Nelson, Daniel; McConville, Brian; Janciuras, Joanne; Bean, Stephen A.; Raab, Dana; Arnold, Francis; Kipp, Heidi; Pearson, Nancy; Vierhile, Amy; Russell, Brad; Tresco, Katy; Cannon, Michael; Maher, Susan; Marcus, David; Riggs, Garrett; Robb, Adelaide; Harris, Peter; Richard, Irene; Sulkes, Stephen; Christopher Cox, Cox; Kurlan, Roger; Conners, Keith; Hunt, Robert; Kieburtz, Karl; De Blieck, Elisabeth; Lindsay, Patricia; Preston, Larry; Rothenburgh, Karen; Julian-Baros, Elaine; Orme, Connie; Kamp, Dee; Thompson, Lisa.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 47, No. 2, 02.2008, p. 180-188.

Research output: Contribution to journalArticle

Palumbo, DR, Sallee, FR, Pelham, WE, Bukstein, OG, Daviss, WB, McDermott, MP, Burrows-MacLean, L, Como, P, Hoffman, MT, Lock, T, Nelson, D, McConville, B, Janciuras, J, Bean, SA, Raab, D, Arnold, F, Kipp, H, Pearson, N, Vierhile, A, Russell, B, Tresco, K, Cannon, M, Maher, S, Marcus, D, Riggs, G, Robb, A, Harris, P, Richard, I, Sulkes, S, Christopher Cox, C, Kurlan, R, Conners, K, Hunt, R, Kieburtz, K, De Blieck, E, Lindsay, P, Preston, L, Rothenburgh, K, Julian-Baros, E, Orme, C, Kamp, D & Thompson, L 2008, 'Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 47, no. 2, pp. 180-188. https://doi.org/10.1097/chi.0b013e31815d9af7
Palumbo, Donna R. ; Sallee, Floyd R. ; Pelham, William E. ; Bukstein, Oscar G. ; Daviss, W. Burleson ; McDermott, Michael P. ; Burrows-MacLean, Lisa ; Como, Peter ; Hoffman, Martin T. ; Lock, Thomas ; Nelson, Daniel ; McConville, Brian ; Janciuras, Joanne ; Bean, Stephen A. ; Raab, Dana ; Arnold, Francis ; Kipp, Heidi ; Pearson, Nancy ; Vierhile, Amy ; Russell, Brad ; Tresco, Katy ; Cannon, Michael ; Maher, Susan ; Marcus, David ; Riggs, Garrett ; Robb, Adelaide ; Harris, Peter ; Richard, Irene ; Sulkes, Stephen ; Christopher Cox, Cox ; Kurlan, Roger ; Conners, Keith ; Hunt, Robert ; Kieburtz, Karl ; De Blieck, Elisabeth ; Lindsay, Patricia ; Preston, Larry ; Rothenburgh, Karen ; Julian-Baros, Elaine ; Orme, Connie ; Kamp, Dee ; Thompson, Lisa. / Clonidine for attention-deficit/hyperactivity disorder : I. Efficacy and tolerability outcomes. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2008 ; Vol. 47, No. 2. pp. 180-188.
@article{dc7e0b563e8c4cdfb94d6b3dc2974d64,
title = "Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes",
abstract = "OBJECTIVE: To determine the efficacy and safety of clonidine, used alone or in combination with methylphenidate, in treating attention-deficit/ hyperactivity disorder (ADHD). METHOD: A 16-week, randomized, double-blind, placebo-controlled clinical trial was conducted in 122 children, ages 7 to 12, with any subtype of ADHD, randomly assigned to clonidine, methylphenidate, clonidine in combination with methylphenidate, or placebo according to a 2 × 2 factorial design. In two successive 4-week titration periods, clonidine (or matching placebo) and added methylphenidate (or matching placebo) were adjusted to optimal doses and then continued for 8 weeks. The primary efficacy outcome was changed from baseline to week 16 on the Conners Teachers Abbreviated Symptom Questionnaire. Secondary outcomes included the Conners Abbreviated Symptom Questionnaire for Parents and the Children's Global Assessment Scale. RESULTS: On the Conners Teachers Abbreviated Symptom Questionnaire, clonidine was not found to improve ADHD symptoms, whereas subjects treated with methylphenidate showed significant improvement compared to those not treated with methylphenidate. Subjects treated with clonidine had greater improvements on the Conners Abbreviated Symptom Questionnaire for Parents and Children's Global Assessment Scale, but also a higher rate of sedation compared with subjects not treated with clonidine. CONCLUSIONS: Based on the Conners Teachers Abbreviated Symptom Questionnaire, methylphenidate offers the best combination of efficacy and tolerability for ADHD. Clonidine was well tolerated despite the frequency of sedation and did offer some benefit. Copyright 2008",
keywords = "Attentiondeficit/hyperactivity disorder, Clinical trials, Clonidine, Methylphenidate",
author = "Palumbo, {Donna R.} and Sallee, {Floyd R.} and Pelham, {William E.} and Bukstein, {Oscar G.} and Daviss, {W. Burleson} and McDermott, {Michael P.} and Lisa Burrows-MacLean and Peter Como and Hoffman, {Martin T.} and Thomas Lock and Daniel Nelson and Brian McConville and Joanne Janciuras and Bean, {Stephen A.} and Dana Raab and Francis Arnold and Heidi Kipp and Nancy Pearson and Amy Vierhile and Brad Russell and Katy Tresco and Michael Cannon and Susan Maher and David Marcus and Garrett Riggs and Adelaide Robb and Peter Harris and Irene Richard and Stephen Sulkes and {Christopher Cox}, Cox and Roger Kurlan and Keith Conners and Robert Hunt and Karl Kieburtz and {De Blieck}, Elisabeth and Patricia Lindsay and Larry Preston and Karen Rothenburgh and Elaine Julian-Baros and Connie Orme and Dee Kamp and Lisa Thompson",
year = "2008",
month = "2",
doi = "10.1097/chi.0b013e31815d9af7",
language = "English (US)",
volume = "47",
pages = "180--188",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Clonidine for attention-deficit/hyperactivity disorder

T2 - I. Efficacy and tolerability outcomes

AU - Palumbo, Donna R.

AU - Sallee, Floyd R.

AU - Pelham, William E.

AU - Bukstein, Oscar G.

AU - Daviss, W. Burleson

AU - McDermott, Michael P.

AU - Burrows-MacLean, Lisa

AU - Como, Peter

AU - Hoffman, Martin T.

AU - Lock, Thomas

AU - Nelson, Daniel

AU - McConville, Brian

AU - Janciuras, Joanne

AU - Bean, Stephen A.

AU - Raab, Dana

AU - Arnold, Francis

AU - Kipp, Heidi

AU - Pearson, Nancy

AU - Vierhile, Amy

AU - Russell, Brad

AU - Tresco, Katy

AU - Cannon, Michael

AU - Maher, Susan

AU - Marcus, David

AU - Riggs, Garrett

AU - Robb, Adelaide

AU - Harris, Peter

AU - Richard, Irene

AU - Sulkes, Stephen

AU - Christopher Cox, Cox

AU - Kurlan, Roger

AU - Conners, Keith

AU - Hunt, Robert

AU - Kieburtz, Karl

AU - De Blieck, Elisabeth

AU - Lindsay, Patricia

AU - Preston, Larry

AU - Rothenburgh, Karen

AU - Julian-Baros, Elaine

AU - Orme, Connie

AU - Kamp, Dee

AU - Thompson, Lisa

PY - 2008/2

Y1 - 2008/2

N2 - OBJECTIVE: To determine the efficacy and safety of clonidine, used alone or in combination with methylphenidate, in treating attention-deficit/ hyperactivity disorder (ADHD). METHOD: A 16-week, randomized, double-blind, placebo-controlled clinical trial was conducted in 122 children, ages 7 to 12, with any subtype of ADHD, randomly assigned to clonidine, methylphenidate, clonidine in combination with methylphenidate, or placebo according to a 2 × 2 factorial design. In two successive 4-week titration periods, clonidine (or matching placebo) and added methylphenidate (or matching placebo) were adjusted to optimal doses and then continued for 8 weeks. The primary efficacy outcome was changed from baseline to week 16 on the Conners Teachers Abbreviated Symptom Questionnaire. Secondary outcomes included the Conners Abbreviated Symptom Questionnaire for Parents and the Children's Global Assessment Scale. RESULTS: On the Conners Teachers Abbreviated Symptom Questionnaire, clonidine was not found to improve ADHD symptoms, whereas subjects treated with methylphenidate showed significant improvement compared to those not treated with methylphenidate. Subjects treated with clonidine had greater improvements on the Conners Abbreviated Symptom Questionnaire for Parents and Children's Global Assessment Scale, but also a higher rate of sedation compared with subjects not treated with clonidine. CONCLUSIONS: Based on the Conners Teachers Abbreviated Symptom Questionnaire, methylphenidate offers the best combination of efficacy and tolerability for ADHD. Clonidine was well tolerated despite the frequency of sedation and did offer some benefit. Copyright 2008

AB - OBJECTIVE: To determine the efficacy and safety of clonidine, used alone or in combination with methylphenidate, in treating attention-deficit/ hyperactivity disorder (ADHD). METHOD: A 16-week, randomized, double-blind, placebo-controlled clinical trial was conducted in 122 children, ages 7 to 12, with any subtype of ADHD, randomly assigned to clonidine, methylphenidate, clonidine in combination with methylphenidate, or placebo according to a 2 × 2 factorial design. In two successive 4-week titration periods, clonidine (or matching placebo) and added methylphenidate (or matching placebo) were adjusted to optimal doses and then continued for 8 weeks. The primary efficacy outcome was changed from baseline to week 16 on the Conners Teachers Abbreviated Symptom Questionnaire. Secondary outcomes included the Conners Abbreviated Symptom Questionnaire for Parents and the Children's Global Assessment Scale. RESULTS: On the Conners Teachers Abbreviated Symptom Questionnaire, clonidine was not found to improve ADHD symptoms, whereas subjects treated with methylphenidate showed significant improvement compared to those not treated with methylphenidate. Subjects treated with clonidine had greater improvements on the Conners Abbreviated Symptom Questionnaire for Parents and Children's Global Assessment Scale, but also a higher rate of sedation compared with subjects not treated with clonidine. CONCLUSIONS: Based on the Conners Teachers Abbreviated Symptom Questionnaire, methylphenidate offers the best combination of efficacy and tolerability for ADHD. Clonidine was well tolerated despite the frequency of sedation and did offer some benefit. Copyright 2008

KW - Attentiondeficit/hyperactivity disorder

KW - Clinical trials

KW - Clonidine

KW - Methylphenidate

UR - http://www.scopus.com/inward/record.url?scp=38549149224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549149224&partnerID=8YFLogxK

U2 - 10.1097/chi.0b013e31815d9af7

DO - 10.1097/chi.0b013e31815d9af7

M3 - Article

VL - 47

SP - 180

EP - 188

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 2

ER -